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Human immunodeficiency virus (HIV) is a preventable cause of disease that infects 
approximately 50,000 individuals annually in the United States. Not all individuals are impacted 
equally and health disparities exist among racial, ethnic, and sexual minorities. Routine 
screening for HIV has been effective in certain populations, but widespread testing has been 
limited. National guidelines call for routine HIV screening among individuals aged 13-64 years 
seeking healthcare; however, implementation has been hindered due to barriers at the individual, 
health system, and societal level. HIV prevention counseling is also recommended for high risk 
individuals, but not required as part of routine testing because of time and staffing restraints. A 
number of HIV testing program interventions have sought to streamline testing and counseling 
procedures to combat such barriers. This review aims to summarize HIV testing and counseling 
programs in the U.S., the effect on individual and public health, and offer directives for future 
use of HIV screening. The public health importance for increasing knowledge of HIV status will 
benefit HIV positive individuals by promoting early entry into care and faster time to treatment. 
Both HIV positive and negative individuals may benefit from HIV prevention education to 
reduce their risk for transmitting or acquiring HIV, thus control the spread of infection.   
Simon M. Barratt-Boyes, BVSc, PhD 
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1.0  INTRODUCTION 
 
In the United States an estimated 15.8% of individuals living with human 
immunodeficiency virus (HIV) infection are unaware of their status and many continue to 
propagate the HIV epidemic by unknowingly spreading the virus to others.1,2 In 2009, 32% of 
individuals newly diagnosed with HIV infection progressed to acquired immunodeficiency 
syndrome (AIDS) within one year, suggesting these individuals have been living with HIV for 
years and gone undiagnosed.3,4 Identifying and diagnosing HIV positive individuals at the 
earliest stage possible is crucial to not only benefit the individual by getting them into care, but 
to benefit public health by controlling HIV transmission by those unaware they are positive. 
Broadening and increasing HIV testing to identify HIV positive individuals promotes early entry 
into care and faster time to highly active anti-retroviral treatment (HAART) to improve health 
outcomes. Knowledge of one’s HIV positive status has been shown to significantly reduce high 
risk behavior lowering the likelihood of transmitting HIV, thus controlling the spread of 
infection.5 In addition, HIV negative individuals can benefit from HIV prevention education to 
practice risk reduction or to avoid acquiring HIV infection. Currently there is no cure for HIV 
and AIDS. Vaccines and microbicides offer hope, yet none exist to date that effectively prevent 
infection.  
Prevention of HIV relies heavily on identifying at risk individuals and confirming their 
HIV status to implement behavioral changes that can lead to healthier lives and prevent HIV 
transmission, which begins with HIV testing. This review aims to summarize HIV testing and 
counseling as a mechanism to prevent and control HIV among vulnerable populations in the U.S. 
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and to provide an example of a coordinated care approach at the Pittsburgh AIDS Task Force in 
Pittsburgh, PA. 
 
1.1 HIV/AIDS TRENDS IN THE UNITED STATES 
 
In the U.S., approximately 1.1 million people aged 13 and older are living with HIV and 
nearly 50,000 new infections occur each year.6 In 2011, the Centers for Disease Control and 
Prevention (CDC) estimated 49,273 incident HIV infections.7 Mortality due to HIV progression 
to AIDS has declined dramatically since the initiation of HAART;8,9,10,11 however AIDS-related 
deaths still occurred in over 15,000 individuals in 2010.7 The cumulative estimation for total 
AIDS-related deaths in the U.S. reaches over 635,000.7  Southern U.S. has the highest percentage 
(48%) of total AIDS-related deaths. When factoring in population size, the Northeastern region 
of the U.S. accounted for the highest rates of individuals living with AIDS and AIDS-related 
deaths.12  HIV tends to localize to urban areas, with most cases in metropolitan areas defined as 
greater than or equal to 500,000 people. In 2011, California, Florida, Texas, and New York had 
the greatest number of cases with HIV infection diagnosis. The District of Columbia, Louisiana, 
Maryland, and Florida had the highest rates of new HIV diagnosis.13  
Racial and ethnic groups differ with respect to the impact from the HIV epidemic (Figure 
1). African Americans account for the highest number of new HIV diagnosis followed by whites, 
Hispanic and Latino, Asian, Multiple Race, American Indian and Alaska Native, and Native 
Hawaiian and Other Pacific Islander.7 This view changes with respect to the rates of HIV 
infection diagnosis for each racial or ethnic group’s representation of the U.S. population.3 
African Americans remain the most affected by HIV, especially young men who have sex with 
men (MSM). Hispanic and Latinos are disproportionately affected by HIV infection and account 
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for approximately 21% of all new infections.3,7 Native Hawaiians and Other Pacific Islanders 
account for a small percent of the overall population, though have a higher estimated rate of 
individuals unaware of their HIV positive status and the highest proportion of late HIV 
diagnosis, defined as progression to AIDS within one year. American Indians and Alaska 
Natives have the second highest proportion of late HIV diagnosis. Whites and Asians have the 
lowest rates of new HIV infection and late diagnosis when their representation of the U.S. 
population is factored. 3,7 
 
 
Figure 1. Estimated HIV diagnoses among adults and adolescents by race and ethnicity7  
 
Transmission of HIV occurs through infected blood, semen, vaginal and cervical fluid, 
and breast milk. The major modes of transmission are unprotected anal and vaginal sex or use of 
HIV contaminated shared needles for injection drug use (IDU). Transmission categories can be 
defined as male to male transmission, high risk heterosexual contact, and IDU of shared needles, 
as shown in Figure 2. Other modes of transmission include perinatal exposure or blood 
transfusion with HIV infected blood. HIV transmission has been significantly reduced in the U.S. 
due to universal HIV screening of all blood donations. The availability of antiretroviral treatment 
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for HIV positive pregnant women has significantly decreased cases of perinatal acquired HIV 
infection.14,15  
Overall, men account for a higher proportion of HIV incidence and prevalence than 
women. In 2010, males represented 76% of individuals living with HIV and 69% considered 
themselves gay, bisexual, or MSM, representing the most significantly affected group by the 
HIV epidemic in the U.S. Sexual activity between men is the primary route of transmission (78% 
of new HIV infection in men, 63% of total new HIV infections).7 Approximately 1 in 4 
individuals living with HIV are female and high risk heterosexual contact is the primary route of 
transmission (84% of new HIV infections in women). High risk heterosexual contact includes 
unprotected sex, sex with multiple partners, sex with a person who is HIV positive or highly at 
risk for HIV infection.  
 
  
Figure 2. Estimated HIV diagnoses among adults and adolescents by transmission7 
 
In most cases, the risk for acquiring and transmitting HIV begins at the onset of high risk 
sexual activity or IDU and continues as long as such behavior continues. The impact of HIV 
diagnosis on different age groups is varied (Figure 3), but estimates show younger individuals 
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aged 13-29 are at an increased risk for new infection, especially young African American and 
Hispanic/Latino MSM. In 2009, MSM aged 13-29 represented 69% of incident HIV infections 
among MSM and 27% of all new HIV infections.7 Children less than 13 years of age mainly 
acquired HIV via mother-to-child transmission, and in 2011 an estimated 127 children acquired 
HIV.7 In the U.S., perinatal transmission has been greatly reduced by screening pregnant women 
for HIV and treating HIV positive pregnant women with HAART to reduce viral load to 
undetectable levels.15,16 HIV positive pregnant mothers often deliver through caesarean section 
to reduce HIV transmission and do not breast feed.17,18 
 
 
Figure 3. Estimated HIV diagnoses among adults and adolescents by age7 
 
1.2 DISPARITIES IN PREVENTION AND CONTROL OF HIV 
 
HIV incidence among subpopulations in the U.S. based on gender, race/ethnicity, and 
transmission category are shown in Figure 4. The impact of HIV on certain subpopulations is 
disproportionate to their representation of the U.S. population. These vulnerable groups represent 
small portions of the population, yet over represent the burden of HIV infection.  Disparities in 
HIV infection among subpopulations can be viewed by race/ethnicity and sexual orientation, 
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though there is overlap among groups. Vulnerable populations highly susceptible to contracting 
and spreading HIV present a unique challenge to HIV testing efforts.19,20  
Racial and ethnic minorities are highly impacted by HIV/AIDS. African Americans, who 
represent 12% of the U.S. population, account for 44% of Americans living with HIV/AIDS, 
44% of new HIV infections, and 40% of total HIV-related deaths.3,7 Racial disparities exist in the 
percent estimated lifetime risk of becoming HIV-infected where 1 in 70 white Americans 
compared to 1 in 22 African Americans will become infected with HIV.21 African American 
males are 6 times more likely to acquire HIV than white males and African American females 
are 16 times more likely than white females.21 MSM transmission is the number one cause of 
new HIV infection in African American males (73%) and heterosexual contact is the most 
common cause of new infection in females (85%).6 African Americans are most affected by 
HIV/AIDS compared to other races with 475,000 cumulatively diagnosed with AIDS, an 
estimated 20,000 will be diagnosed with HIV, and 16,000 will be newly diagnosed with AIDS. 
3,6 Among youths aged 13-24, HIV disparately affects African Americans where 20% of new 
HIV infections occur in all youths, 65% of youth HIV diagnosis occurs in African Americans 
with an increased risk in youth MSM.6 Hispanics and Latinos are also disproportionately affected 
by HIV, representing 17% of the U.S. populations, but accounting for 21% of all new HIV 
infections and 19% of persons living with HIV/AIDS. 3,6,22  
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Figure 4. HIV infection estimates for most affected subpopulations in the U.S.3 
 
An investigation of 91,307 HIV-related deaths in individuals aged 25-64 from 1993-2007 
assessed HIV mortality trends among racial and ethnic minorities by gender and education 
level.23 This study defined socioeconomic status by least education (≤12 years high school), 
some education (13-15 years some college), and most education (>16 years graduate or 
postgraduate). HIV caused mortality was highest in least educated African American males (53 
per 100,000 black men compared to 5 per 100,000 white men). HIV caused mortality rates in 
least educated African American women were 30 per 100,000 pre-HAART compared to 27 per 
100,000 post-HAART.23 Higher mortality rates were observed in African Americans, especially 
with low income and less education. The study found no improvement in HIV mortality rates 
among African American women despite the advent of antiretroviral therapy.23,24,25  
Based on sexual orientation, MSM remain the number one most vulnerable population 
affected by HIV in the U.S., and HIV infection among this population has significantly increased 
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12% from 2008 to 2010.7 The CDC estimates MSM represent only 4% of the male population, 
yet account for 63% of all new HIV infections.26 HIV infection increased 22% among MSM 13-
24 years old, with African Americans disproportionately affected.  From 2008 to 2010, HIV 
infections among young African American MSM increased by 20%.3,7 Among MSM, Hispanics 
and Latinos accounted for 22% of new HIV infections, with 39% of new infections occurring in 
young MSM aged 25-34. While not disproportionally affected, white MSM are greatly impacted 
by HIV accounting for 38% of new HIV infections, of which 29% of new infections were seen in 
MSM aged 25-34. Long-term data are lacking about the HIV impact on male to female 
transgender women and female to male transgender men; however, recent statistics suggest male 
to female transgender women are at an increased risk for new HIV infection. 27,28 Even less data 
exist on the impact of HIV infection on transgender men, though focus is increasing. There are 
many factors contributing to disparities in HIV infection among vulnerable populations, as 
summarized in Table 1.  
Table 1. Common factors associated with HIV infection disparities23,29-39 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
HIV Disparity Causes Individual and Societal Factors 
Socioeconomic status Lack of permanent housing and homelessness 
Intravenous drug use or active substance abuse 
Incarceration 
Limited education 
Limited access to healthcare Gaps in employment with medical coverage 
Limited access to mental and behavioral health care 
Language barriers 
Lack of permanent housing and homelessness 
Incarceration 
Foster care 
Welfare system 
Differences in infection 
rates 
Tendency to have sex partners within the same race 
Higher rates of STIs in minorities that increase risk 
Possible unknown genetic mechanism 
Lack of physician awareness Not practicing routine testing 
9 
of high risk groups Overwhelmed workload 
Avoidance of uncomfortable topics (e.g. sex, LGBT, drug use) 
Cultural incompetence for minority familial and relationship 
values, community influence, and historical perspectives  
Cultural incompetence for minority and gender risk behaviors 
(e.g. sexual abuse, physical abuse, violence) 
Lack of racial and ethnic minority investigators 
Social stigma and 
marginalization 
Historical impact 
Social, economic, and political inequality 
Fear, discrimination, homophobia still exist 
Magnified in LGBTQI and IDU populations 
Lack of HIV prevention 
knowledge  
Cultural, religious, or philosophical beliefs do not support open 
sex or risk behavior discussion 
Lack of risk reduction education 
Institutional and historical barriers 
Unknown testing status Not-routinely offered in health care settings 
Fear of health insurance or job loss 
Stigma and social issues 
Privacy concerns 
Distrust of practitioners 
Fear of disclosure 
Delays in diagnosis and 
length of time to begin 
HAART 
HIV testing is not  routinely offered in health care settings 
Lack of focus directed on high risk individuals 
Misconceptions surrounding medical insurance coverage 
Poor treatment from health care professionals 
Substance abuse, mental health conditions, or homelessness 
Poor adherence to 
medications 
Fear of health care settings and social stigma 
Medication side-effects 
Substance abuse, homelessness, psychological issues 
Other needs trump own medical needs 
Lack of social and peer support systems 
Comorbid conditions Symptoms mask HIV symptoms and lead to misdiagnosis 
Patients with co-conditions not being routinely HIV tested 
1.3 CURRENT TESTING TRENDS FOR HIV 
HIV testing is conducted at a variety of settings.40 Healthcare settings include hospital, 
emergency room, private doctor, outpatient clinic, public health department clinic, drug 
Table 1 Continued
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treatment facility, correctional facility, family planning clinic, prenatal clinic, sexually 
transmitted disease (STD) clinic, or community health clinic. Non-healthcare settings include 
AIDS counseling and testing site, employer or insurance company clinic, military service site, 
immigration site, home, and other non-clinical setting such as bars, community organizations, or 
mobile testing sites. Both healthcare and non-healthcare settings can be publicly funded and 
include public health departments, drug treatment facilities, family planning centers, prenatal 
clinics, STD clinics, community health clinics, AIDS testing and counseling sites, while 
hospitals and emergency rooms are primarily privately funded.  
Over the past decade, HIV testing trends in the U.S. were assessed for ever been tested or 
been tested in the last 12 months.41 Results varied depending on the data source. Primarily, 
trends for gender, race and ethnicity showed significant increases or no change in HIV testing 
ever or in the last 12 months; however significant decreases were observed for tested in the last 
12 months for white race and other race/ethnicity. Increased testing or no change was also seen 
in all age groups except for young adults 18-24 years of age. Trends for HIV infection are high 
for individuals aged 13-29, yet younger persons were less likely to have been HIV tested.  Data 
from National Health and Nutrition Examination Survey (NHANES) found a significant 
decrease in ever been tested for this age group. The National Health Interview Survey (NHIS) 
reported significant decreases for ever been tested and tested in the last 12 months in non-
healthcare settings.  
Cost analyses have found overall, HIV testing in both healthcare and non-healthcare 
settings is cost effective.42,43,44 The Assessment of 2010 CDC-funded Health Department HIV 
Testing Spending and Outcomes found testing in non-healthcare settings required more cost than 
healthcare settings; however, non-healthcare settings diagnosed more HIV positive individuals.45 
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In non-healthcare settings, costs were 9 times higher per testing event and 5 times higher per 
newly identified confirmed HIV positive diagnosis. Costs were higher due to infrastructure 
expenses and recruitment costs associated with reaching high risk populations who do not 
regularly seek clinical care. Non-healthcare settings cast a wider net than healthcare settings, 
which is crucial for reaching populations who do not actively seek out providers to identify HIV 
positive individuals and link them to care.  
In healthcare settings, the CDC recommends HIV screening for patients aged 13-64 given 
the patient is notified testing will be performed and given the option to decline or opt-out.46 HIV 
screening should be incorporated into general consent for medical care and separate written 
consent is not recommended. Prevention counseling as part of HIV testing programs in 
healthcare settings is also not recommended; however, jurisdiction over consent, pre-test and 
post-test counseling is regulated at the state level and not all states have adopted opt-out HIV 
screening.  
In July of 2010, the White House released the National HIV/AIDS Strategy (NHAS), the 
first U.S. comprehensive and coordinated HIV/AIDS roadmap with measurable goals to be 
achieved by 2015.47 The CDC supports efforts to implement the NHAS, which include action 
steps to reduce new HIV infection, increase access to care and improve health outcomes for 
people living with HIV,  reduce HIV related disparities and health inequities, and achieve a more 
coordinated national response to the HIV epidemic. One of the measurable goals is to increase 
the number of individuals living with HIV who are aware of their status from 79% to 90%. 
Another strategy is to improve monitoring, reporting, and coordination of HIV programs across 
and between the federal, state, tribal, and local governments and agencies.47   
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1.4 KNOWLEDGE OF HIV TESTING STATUS 
 
It is estimated that 15.8% of individuals living with HIV are unaware of their HIV 
positive status.1 The likelihood these individuals continue to unknowingly transmit the virus to 
others resulting in the spread of infection is high. HIV positive individual with unknown testing 
status are unlikely to reduce high risk behaviors such unprotected sex, sex with multiple partners, 
or IDU needle sharing.48,49,50 Knowledge of HIV status has been linked to behavioral changes 
that decrease risky behavior practice and promote harm reduction to reduce transmission to 
sexual or needle-sharing partners.2,51,52,53,54,55,56,57 Primary HIV infection is the time after 
infection before an individual’s immune system has generated HIV specific antibodies to combat 
the virus.58 Individuals in this acute stage of HIV infection are highly infectious and at an even 
higher risk of transmitting HIV.59,60    
Over time, lack of HIV testing status awareness can lead to increased morbidity and 
mortality in HIV positive individuals. The majority of AIDS-related deaths occur from 
opportunistic infections that thrive due to the individuals weakened immune system. Treatment 
with antiretroviral therapy, primarily HAART, lowers HIV viral load by suppressing viral 
replication and increasing CD4+ T-lymphocytes thereby improving immune function to 
significantly delay progression to AIDS.8,9,10,11 By maintaining the immune system, HAART has 
dramatically reduced the number of opportunistic infections and improved survival rates for 
persons living with HIV. Viral load suppression also offers protection for sex partner, prevents 
mother-to-child transmission, and improves the quality of life for the person with HIV. Faster 
time to treatment results in better control of the HIV virus and better health outcomes; however, 
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to be able to take advantage of highly effective HIV therapy individuals must know their testing 
status first.61  
To increase awareness of HIV status the CDC established the Expanded Testing Initiative 
(ETI), which included PS07-768: Expanded and Integrated HIV Testing for Populations 
Disproportionately Affected by HIV, Primarily African American (2007-2010), followed by 
PS10-10138: Expanded HIV Testing for Disproportionately Affected Populations (2010-2011), 
and currently PS12-1201: Comprehensive HIV Prevention Programs for Health Departments 
(2012-2017).62 The purpose of the ETI is to significantly increase the number of individuals 
tested in regions with high rates of HIV among disproportionately affected populations and to 
support implementation of the CDC recommendations for HIV testing in healthcare settings. 
Through PS07-768, the CDC funded jurisdictions in high HIV burdened areas to increase HIV 
testing, linkage to medical care, and prevention services. Over a 3 year period, 2,786,739 HIV 
tests were conducted and 18,432 (0.7%) were newly identified confirmed HIV positive, of which 
74.3% were linked to HIV medical care.62 PS10-10138 and PS12-1201 were designed to 
continue the progress made under PS07-768 and expand routine HIV testing services for other 
high risk populations, including Hispanic men and women, MSM and IDU by funding more 
jurisdictions. 
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2.0  SECOND CHAPTER: HIV TESTING AND COUNSELING 
HIV testing was first introduced in 1985 to screen blood donors and reduce transmission 
via blood transfusions. By 1987 the implications of testing HIV positive became apparent and 
the first set of guidelines were established by the U.S. Public Health Service (USPHS) calling for 
routine testing and counseling among high risk individuals seeking STD treatment.63 Six years 
later, the CDC extended recommendations for voluntary HIV testing and counseling to hospitals, 
acute care settings, and emergency departments. Dependent on HIV/AIDS rates, hospitals were 
encouraged, not required, to routinely offer voluntary counseling and HIV testing to all patients 
15-54 years of age. Voluntary and confidential testing, documented informed consent, and 
explanation of testing was recommended.64 Client-centered counseling to assess high risk 
behaviors, develop tailored prevention plans, and safer goal strategies was introduced in 1994.65  
Voluntary HIV testing and counseling was recommended in all pregnant women in 1995 
by the USPHS after treatment with anti-retroviral medication resulted in significant reduction in 
perinatal HIV transmission.66,67 To reduce barriers of HIV testing in pregnant women, the CDC 
modified these recommendations in 2001 simplifying counseling and the consent process.68 
Health-care settings were expanded to include private and publicly funded clinics to improve 
access of HIV testing. The 2001 guidelines also suggested testing be routinely offered to all 
patients in high HIV prevalent settings, and targeted HIV testing by doing risk assessment be 
implemented in areas with low HIV prevalence.69 
Providers and patients found that discomfort discussing sensitive topics, time restrictions, 
and written informed consent presented as barriers to HIV testing.70,71 To combat this issue, the 
CDC created a new initiative in 2003 called Advancing HIV Prevention: New Strategies for a 
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Changing Epidemic, to make routine voluntary HIV testing part of medical care at the same level 
as other diagnostic and screening tests, implement new models for diagnosing HIV outside 
medical settings, focus prevention on HIV-infected persons and their partners, and decrease 
perinatal HIV transmission by universal rapid testing of all pregnant women, prenatally, during 
labor and delivery, or postpartum.72 HIV prevention counseling was considered desirable for 
high risk individuals, but not always feasible.73  
The CDC Revised Recommendations for HIV Testing of Adults, Adolescents, and 
Pregnant Women in Health-Care Settings, 2006, are in circulation today.74 From 2004-2006, the 
CDC utilized a multi-disciplinary approach and solicited the aid of health-care providers, 
professionals, local health officials, public health agencies, researchers, clinicians, community 
organizations, HIV specific care givers and persons living with HIV to provide feedback on how 
broaden and increase HIV testing, especially for those at high risk. The final recommendations 
were produced in response to evidence that feasibility of increased HIV testing would improve 
by simplifying the process, which would also lower costs. Of note, the CDC does not 
recommend prevention counseling with HIV testing in healthcare settings because it is seen as a 
barrier to testing; however, prevention counseling is recommended for persons at high risk for 
HIV and in non-medical settings. The CDC also recommended utilization of opt-out HIV testing, 
where the individual is notified the HIV test will be performed and consent is inferred unless the 
individual declines. Opt-in HIV testing requires an individual explicitly consents in writing to 
receive an HIV test. 
The 2010 CDC Sexually Transmitted Disease Treatment Guidelines recommendations for 
Detection of HIV Infection: Screening and Establishing a Diagnosis include opt-out HIV 
screening part of routine healthcare for all individuals aged 13-64 years.46 The CDC also calls for 
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routing screening for all individuals seeking STD evaluation regardless of specific HIV risk 
behavior and re-screening high risk individuals every 3-6 months. The guidelines suggest 
routinizing HIV testing in combination with other tests, such as blood pressure and cholesterol, 
will aid in identifying and diagnosing HIV positive individuals and help reduce stigma that may 
present as a barrier to testing. The U.S. Preventive Services Task Force (USPSTF) recommends 
routine HIV screening for everyone aged 15-65 years and targeting screening in those aged less 
than 15 and greater than 65 years who are at high risk for HIV infection. 
In the U.S., mandates and laws regarding HIV testing and counseling are governed by 
laws enacted at the state level.75 Although the federal government does not have jurisdiction over 
state mandates regarding HIV testing, 90.2% of states adopted or revised testing laws considered 
compatible with the 2006 CDC recommendations.76 Variations among HIV testing laws occur 
from state to state for opt-in versus opt-out informed consent, HIV pre- and post-test counseling, 
availability of anonymous testing, required partner notification, implementation of routine HIV 
testing, rapid and confirmatory testing, and provisions regarding minor and adolescent testing.77 
Mandates around HIV testing also vary between states for different settings such as healthcare 
facilities, correctional institutions, substance abuse or mental health treatment centers. 
 
2.1 CURRENT HIV TESTS AND PROCEDURES 
 
Advances in HIV testing have improved the simplicity, reliability, and safety of 
conducting testing in healthcare and non-healthcare settings. There are two different modes of 
detection for HIV tests: HIV antibody production and HIV viral load. Conventional antibody 
tests are enzyme immunoassays (EIA) or enzyme-linked immunosorbent assays (ELISA) and 
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can be performed on blood or oral fluid in a laboratory. Test results are usually available 
between 2-14 days. Rapid antibody tests are point-of-care tests that can also be performed on 
blood by finger prick or oral fluid with a result turnaround time of 20-40 minutes and are highly 
sensitive.78,79 Antibody tests can be classified as 1st, 2nd, 3rd, and 4th generation based on the 
antibodies they detect: 2nd generation detects IgG antibodies; 3rd generation detects IgM and IgG 
antibodies; and 4th generation detects HIV antibodies and the HIV viral p24 antigen.78  
Antibody test negative results indicate the test did not detect HIV antibodies and are 
considered definitive for no HIV infection given the time point of exposure. The window period, 
which is the time it takes for HIV antibodies to develop after infection, can take up to 3 months 
after exposure to HIV.80,81 This is critical for a HIV antibody tests to be definitive. Individuals 
seeking antibody testing, should be made aware of the window period and advised to retest 3 
months after the point of known or possible exposure, such as unprotected sex or shared needle 
IDU. Antibody test positive results are considered preliminary positive for detection of HIV 
antibodies and require confirmatory testing. HIV confirmatory testing should also be conducted 
for inconclusive antibody test results.  
Confirmatory tests are typically Western blot, HIV viral load test, or an antibody test of a 
different brand.82 HIV antibody tests tend to be highly sensitive and less specific, which means 
they can produce false-positive results. A Western blot, the most common confirmatory test, is a 
highly specific antibody test that has a lower likelihood of yielding a false-positive result. HIV 
viral load tests detect viral RNA by polymerase chain reaction (PCR) and measure the level of 
HIV in blood, which is also commonly performed to monitor viral suppression in HIV positive 
individuals on anti-retroviral medication. If Western blot or HIV viral load tests are not feasible, 
a second antibody test from a different manufacturer can be performed.  
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2.2 HIV COUNSELING FUNDAMENTALS 
 
HIV counseling arms individuals with tools to reduce their risk of acquiring or 
transmitting HIV. Counseling provides an opportunity to confront myths about HIV and 
empower individuals with facts surrounding transmission, infection, and treatment. Individuals 
also have the opportunity to bring up concerns and ask questions. The current CDC guidelines do 
not recommend HIV prevention counseling in healthcare settings due to lack of evidence for 
effectiveness.46 While the CDC provides national recommendations, requirements for HIV 
testing, consent, and counseling vary under state law and some states require pre- and post-test 
counseling. Non-healthcare settings may be more likely to use risk reduction counseling targeted 
at high risk individuals who do not regularly seek medical care. Both healthcare and non-
healthcare settings may benefit from having staff trained in HIV prevention counseling to ensure 
they give information and answer questions correctly. The procedure for HIV prevention 
counseling using a client centered approach is outlined below. 65,69,74   
Pre-test Procedure 
1. Offer the test 
2. Explain the test, how it is used and its limitations 
3. Explain how the results are interpreted 
4. HIV prevention, exposure, and treatment information must be available 
5. Obtained written consent, which can be part of a general medical consent 
 
Post-test Procedure 
1. Provide results for both positive and negative individuals 
2. Explain what the results mean 
3. For test positive patients, a second confirmatory test is necessary and they should avoid 
behavior that could put others at risk (i.e. use condoms during sex or refrain from sex 
altogether) 
4. Provide information about preventing transmission  
5. Explain the benefits of contact tracing or partner services 
6. For test positive individuals: 
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a. Provide referrals for proper health care providers and services 
b. Provide referrals for community and case management services 
c. Provide information regarding HIV  
d. Test results are confidential; however, confirmatory test positive results are 
reported to the health department 
 
Consent: First and foremost, counselors should address with the individual seeking 
testing that all information will remain confidential under the Health Insurance Portability and 
Accountability Act of 1996 (HIPAA) and will not be disclosed to any employment or insurance 
agencies under the Confidentiality of HIV-Related Information Act.83,84 Second, they should 
explain that some of the discussion to follow will surround personal information and sensitive 
topics may be uncomfortable, and that no judgment or assumptions will be made. The goal is to 
inform about the facts on HIV and create a plan to eliminate or reduce HIV risk so they remain 
healthy. If required under state laws, counselors should inform the individual seeking testing that 
in order to perform the HIV test and disclose the results; the individual must sign a consent form. 
This form may contain demographic information useful not only for reporting, but so the 
counselor may gather information such as age, race/ethnicity, and gender useful for assessing 
risk. Counselors should urge the individual to interrupt at any time he or she may feel 
uncomfortable and reassure that information will remain confidential and used to provide the 
best outcome for the individual.   
Assessing risk: Clients may not be aware of their own behaviors that put them at risk for 
HIV infection. By asking open ended questions, such as “What brings you to get testing today?,” 
allows the individual to direct the discussion to suit their needs. Common reasons an individual 
may seek HIV testing include an unprotected sex act, drug use with shared needles, or a 
healthcare professional accidental needle stick. If the individual is hesitant to offer information 
readily, use a combination of open ended questions or direct yes or no questions to gather 
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information on sexual orientation or IDU. The next series of open ended questions should focus 
on the individuals’ circumstance that brought them to seek HIV testing. Circumstances may 
include current and past sexual practices including number of sex partners, gender of each 
partner, condom usage, ever had unprotected sex, forms of birth control, past pregnancy, any 
chance of pregnancy, STI history, substance abuse including tobacco and alcohol use/quantity, 
illegal or prescribed drugs for recreational purposes, and were they injectable or needles were 
used or shared.  
Identify safer goal behaviors: Counselors should help the client understand how a 
specific behavioral change directly links to their risk behavior. For example, always using 
condoms, abstaining from sex acts, always using clean syringes during IDU, or abstaining from 
IDU virtually eliminates the risk of HIV infection. The goal behavior must be attainable and the 
client must be willing to adopt. This may not always be sufficient to eliminate risk for HIV 
infection. If the client is unwilling to completely eliminate a risk factor, identification of alternate 
goals will reduce HIV risk such as reducing the number of sex partners or keeping clean works 
for IDU. Counselors should also discuss previous successes and barriers.  
Create client centered risk elimination or harm reduction plan: Together the counselor 
and client design a specific plan with incremental steps the client can carry out to help adopt 
safer goal behaviors based on the Transtheoretical Model.85 In this model, behavior modification 
occurs through progression of 5 stages: pre-contemplation, contemplation, preparation, action, 
and maintenance. Ideally individuals reach termination and eliminate the unhealthy behavior or 
they may relapse and cycle through the stages several times before termination. At first it may 
seem obvious to simply summarize the safer goal behaviors and tell the client to implement 
them; however, creating a realistic, achievable plan must take into account other circumstances. 
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Clients may have other needs that take prioritization over their own health and risk reduction 
behavior including domestic violence, alcohol and substance abuse, lack of housing, lack of 
transportation, need for childcare, unemployment, mental illness, and incarceration. If warranted, 
referrals should be provided to help guide clients to the proper sources specific for the challenges 
they are facing. Ancillary services are an important link for entry into and retention in HIV care 
including case management, mental health support, substance abuse treatment, transportation, 
childcare, or housing assistance.86,87  Such services aid in efforts to improve the client’s quality 
of life, thus assist in their HIV care and prevention.  
2.3 COORDINATED, COMPREHENSIVE, CARE NETWORKS 
The most successful HIV prevention networks offer programs that are coordinated, 
comprehensive, and care-focused.88,89,90,91 Coordination involves effective communication 
among many disciplines including providers, researchers, counselors, case management, 
community organizations, referral services, insurance agencies, and the client. A comprehensive 
approach includes a wide-range of care services that covers a majority of needs to reach as many 
individuals as possible. The patient or client care should be held to the utmost professional 
standard, making sure resources are reliable, making appropriate and adequate recommendations, 
and integrating the needs of the individual seeking care into the services provided.  
Table 2. Characteristics of a successful HIV care network 
A comprehensive and coordinated HIV care program should include: 
Dedicated and 
experienced team of 
professionals 
⋅ HIV care coordinators 
⋅ Physician (an HIV expert clinician is ideal) 
⋅ Nurses 
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⋅ Pharmacist 
⋅ Counselors trained in HIV prevention 
⋅ Case-manager 
⋅ Administrative staff 
Cover all aspects of 
HIV care 
⋅ Offer HIV testing, prevention and education counseling 
⋅ HIV diagnosis confirmation 
⋅ Promote early entry into care and fast time to treatment 
⋅ Focus on follow-up and retention in care 
⋅ Implement and adhere to current HIV prevention and treatment 
guidelines and recommendations 
Patient confidentiality ⋅ Implement and adhere to HIPAA guidelines 
⋅ No breach of confidentiality will be tolerated 
⋅ Legal repercussions and expulsion will be dealt 
⋅ Teach standards and guidelines to reduce opportunities for 
patient information leaks 
⋅ Utilize electronic medical records to eliminate paper charts 
⋅ Explain how patient trust is imperative to successful HIV care 
⋅ Constant measures to assess in-house care by evaluation and 
quality improvement 
Cultural competence ⋅ Culture differences among minority and ethnic groups 
⋅ LGBTQI community 
⋅ Women’s issues 
⋅ Self-cultural view 
⋅ Increase awareness of cultural values and ethics 
⋅ Increase communication skills across cultures  
⋅ Multi-lingual staff to overcome language barriers 
⋅ Culture friendly waiting and exam rooms 
Strong referral and 
linkage system to 
alternate medical and 
support service 
providers 
⋅ Mental health services 
⋅ Ob-Gyn providers 
⋅ Family planning 
⋅ Substance abuse treatment 
⋅ Homeless services 
Clinicians, supervisors, and care coordinators should lead their team and develop 
workplace policies to improve the quality of care based on the U.S. Department of Health and 
Human Services: Health Resources and Services Administration (HRSA) guidelines for 
HIV/AIDS clinical care and the National Institutes of Health HIV/AIDS related medical practice 
guidelines.92,93 Policies should implement guidelines for cultural competence and patient 
Table 2 Continued
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confidentiality practices for no tolerance work zones and enforce strict repercussions in the event 
of a confidentiality breach. Clinic staff should be educated on addressing different cultures or 
backgrounds without using judgment. In regions with high immigration, hire or make available 
as needed bi-lingual or multi-lingual staff members specific for that demographic. Programs 
should enforce HIPAA guidelines and confidentiality practices. Focus should be placed on the 
imperative role that the patient-clinic relationship factors in HIV care and affects not only the 
patient, but the community including the staff themselves. Evaluation measures should be in 
place to monitor quality of care such as annual completion of competence and confidentiality 
modules, tracking patient follow-up data for improvements, and obtaining patient feedback.  
 
2.4 PITTSBURGH AIDS TASK FORCE HIV TESTING PROGRAM 
 
The Pittsburgh AIDS Task Force (PATF) is a not-for-profit 501(c) (3) organization with 
a mission dedicated to supporting and empowering all individuals living with HIV/AIDS and 
preventing the spread of infection.94 The PATF excels as a HIV/AIDS prevention agency that 
incorporates in house free and confidential HIV testing and counseling with community 
prevention and education outreach. The PATF serves as a model for coordinated and 
comprehensive care from the first stop for individuals seeking HIV testing, case management, 
linkage to care, and discounted pharmaceuticals for HIV positive individuals who qualify under 
the Ryan White CARE Act.95 Ancillary to HIV specific care and treatment, the PATF provides 
comprehensive services including a food pantry, transportation and emergency fund assistance, 
transitional and permanent housing, pro bono legal services, support groups, and advocacy. 
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The PATF conducts free and anonymous HIV testing Sunday through Friday at a location 
accessible to public transportation and at various offsite locations commonly frequented by high 
risk groups.83,84 They perform approximately 2,000 HIV tests annually and provide medical case 
management for over 650 HIV positive individuals. The case management program is critical to 
provide medication assistance and ensure adherence among vulnerable populations who may not 
seek healthcare otherwise. In addition, the PATF has provided housing for 50 individuals living 
with HIV/AIDS. Of those seeking HIV care services, 57% identified as gay, lesbian, or bisexual 
and the majority live below the poverty line.  
In addition to walk-in HIV testing, the PATF has developed a strong network in the 
community and continuously works to expand outreach and opportunities to provide HIV testing 
and prevention education throughout. The PATF targets outreach and recruitment efforts at 
populations who are high risk and underserved in the Greater Pittsburgh Area and Western 
Pennsylvania. HIV transmission rates are highest in men who have sex with men (MSM, 53.9%), 
followed by high risk heterosexual transmission (21.1%), and intravenous drug users (IDU, 
11.6%), with minorities over representing persons living with HIV/AIDS.96  
 
HIV/AIDS in Allegheny County, Pennsylvania, 201096 
• Incidence: 12.51 per 100,000  
• New Diagnosis: 98 HIV & 55 AIDS cases 
• Persons living with HIV/AIDS: 2344 individuals (78% of Western PA) 
⋅ 80.7% Male, 19.3% Female 
⋅ 51.5% White, 39.1% Black, 3.6% Hispanic 
 
To intervene in these vulnerable yet differing populations, the PATF coordinates HIV 
prevention programs including GirlTalk aimed at adolescent females 13-18 years of age, 
GirlFriends aimed at adult females, and the M2M project to reach those at highest risk for HIV 
transmission in the MSM population. The GirlTalk and GirlFriends programs center on 
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empowering women to make healthy and safe lifestyle choices. These projects create a safe and 
fun environment for teen or adult women to come together and discuss health education topic 
including sexual health, HIV, STI’s, substance abuse, peer pressure for teens, domestic violence 
and basic prevention knowledge  in a small group setting. HIV knowledge is assessed and before 
and after education interventions using questionnaires. The GirlTalk program recently increased 
efforts to reach out and recruit girls who are less feminine or more masculine, a vulnerable 
population that has previously gone under the radar with respect to HIV prevention efforts. The 
M2M 1st Wednesday and 4th Tuesday outreach projects offered a safe haven for lesbian, gay, 
bisexual, transgender, queer or questioning, and intersex (LGBTQI) individuals to feel 
comfortable to discuss topics around HIV and sexual orientation while having fun. Workshops 
were designed to aid individuals with employment resources, resume building, interview 
practice, career development, and other topics deemed relevant by the participants.  
All outreach projects aimed to educated high risk individuals and offer free and 
confidential HIV testing. HIV testing is performed using the OraQuick ADVANCE® Rapid 
HIV-1/2 Antibody Test  and results are available in 20 minutes for detection of HIV-1 and HIV-
2 antibodies with 99.3% sensitivity (CI=98.4-99.7%) and 99.8% specificity (CI=99.6-99.9%).97  
The OraSure® HIV-1 Oral Specimen Collection Device is conducted as a follow-up 
confirmatory test for reactive or invalid OraQuick® Rapid test. This confirmatory test also uses 
an oral fluid sample that is sent out for a laboratory-based enzyme immunoassay (EIA) screening 
test and Western Blot, the current gold standard for HIV testing.98  
 HIV prevention often deals with sensitive topics that can be uncomfortable to some. 
Social stigma and stereotyping associated with HIV have marked this disease with shame 
masking efforts to promote prevention and testing. The PATF utilizes a variety of approaches to 
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overcome social fear to engage communities and marginalization to target populations difficult 
to reach. Much of HIV prevention and care is centered on the clients’ needs. Just as no one 
individual is the same, no one program exists to encompass all individuals at risk for HIV, and 
the PATF is constantly evaluating and re-evaluating their programs to capture individuals who 
are underserved.  
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3.0  THIRD CHAPTER: INCREASING HIV TESTING EFFORTS 
 
National guidelines and policies call for improving early HIV diagnosis by increasing the 
number of HIV positive individuals unaware of their status that were offered testing and 
subsequent HIV care and prevention services.99 Healthcare settings are encouraged to implement 
routine HIV testing; however, widespread implementation has been slow.99,100,101,102,103,104 
Rarely does an individual walk into a healthcare provider visit and is offered an HIV test. 
Barriers to increase testing efforts in healthcare settings include cost reimbursement, 
overwhelming provider schedules, lack of time to conduct risk assessment and counseling, and 
lack of HIV trained healthcare staff.44,102,105,106,107 Non-healthcare settings are better suited to 
provide targeted HIV prevention counseling and disseminate HIV education, though counseling 
is not required. Non-healthcare organizations can dedicate more time to each individual seeking 
HIV testing or education, yet there remains a population who do not utilize these services. 
Targeted testing programs in both healthcare and non-healthcare settings have been beneficial 
and acceptable by patients and clients, but still face time and follow-up barriers to identify HIV 
positive individuals.103,107,108,109  
There are a number of evidence based interventions that aim to reduce high risk behavior 
and HIV infection, and some directly measure HIV testing rates. Most studies report reduced 
high risk behavior from brief patient centered risk reduction counseling; however evidence has 
shown mixed effects from risk reduction counseling on reducing HIV and other STI acquisition. 
Tailored interventions were shown to be effective among high risk populations such as MSM and 
African American or Latino minorities.  Onsite rapid HIV testing was shown to be very well 
accepted and effective at increasing receipt of HIV test and results. A program designed to notify 
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sex and needle sharing partners of HIV positive individuals that they are at risk for transmission 
was also very effective in targeting and increasing HIV testing at high risk individuals and 
identifying HIV infection in individuals who were unaware. Evidence based HIV testing and 
counseling interventions are summarized in Table 3. 
Table 3. Evidence based HIV testing and counseling programs 
Study Name Intervention Outcome(s) 
The AWARE 
Randomized 
Clinical 
Trial110  
5012 HIV negative patients aged >18 
were randomized to 2 study arms to 
assess the effect of brief risk reduction 
counseling  on STI acquisition: 
1. Rapid HIV test with brief patient-
centered HIV risk reduction 
counseling  
2. Rapid HIV test with standard
testing information only 
HIV & other STIs measured at 6 months: 
Significant findings for intervention: 
• No difference in 6 month STI incidence
between study arms 
• Suggests no added benefit from brief
patient centered risk reduction counseling 
in reducing STI incidence 
Project 
RESPECT 
Randomized 
Clinical 
Trial111 
5758 HIV negative, heterosexual 
patients aged >14 were randomized to 
4 study arms to assess 2 counseling 
interventions on STI acquisition and 
risk behavior: 
1. 4 enhanced interactive theory based
sessions 
2. 2 brief interactive risk reduction
sessions 
3. 2 brief didactic HIV test
information only sessions  
4. 2 brief didactic HIV test
information only sessions with no 
follow up  
STIs measured at  6 and 12 months:  
Significant findings for interventions: 
Enhanced Counseling 
• Lower rate of STI incidence
• Greater reported condom use, no
unprotected vaginal sex, ≤ 1 sex partner
Brief Counseling 
• Lower rate of STI incidence
• Greater reported no unprotected vaginal
sex, ≤ 1 sex partner, no causal or new
partners
• Suggests brief counseling effectively
lowered STI incidence and had better
retention rates than enhanced counseling
Project 
RESPECT-2 
Randomized 
Clinical 
Trial112 
3,297 HIV negative patients aged 15-
39 were randomized to 2 study arms to 
assess the effect of a booster 
counseling intervention on STI 
acquisition and risk behavior: 
1. 2 brief interactive risk reduction
sessions plus a 3rd booster session at 
6 months  
2. 2 brief interactive risk reduction
sessions 
3. Participants were randomized to
receive a rapid or standard HIV test 
STIs measured at 3, 6, 9, 12 months: 
Significant findings for intervention: 
• Less reported ≥ 2 sex partners or
unprotected sex with non-primary partner 
• No difference for incident STI
• Type of HIV test, rapid versus standard,
did not modify the intervention effects
• Suggests brief counseling+ booster was not
more effective at preventing incident STI,
but did reduce sexual risk behavior
compared to brief counseling only
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National Drug 
Abuse 
Treatment 
Clinical Trials 
Network: HIV 
Rapid Testing 
and 
Counseling 
Study (CTN 
0032)113
1281 HIV negative participants from 
community based drug treatment 
programs were randomized to 3 study 
arms to assess HIV testing and risk 
behaviors: 
1. Onsite rapid HIV testing with HIV
risk reduction counseling 
2. Onsite rapid HIV testing with
testing information only 
3. Referral for offsite HIV testing
Receipt of HIV test and results were 
measured at 1 month and risk behaviors at 6 
months. 
HIV rapid test & confirmed positive cases: 
• 2 onsite with counseling
• 1 onsite with information only
Significant findings for interventions: 
• Greater receipt of HIV test and results in
onsite HIV testing groups than offsite 
• No difference in receipt of HIV test and
results between onsite counseling and 
onsite information only groups 
• No difference in unprotected sex
• Suggest onsite rapid HIV testing increased
receipt of test and results and identified
HIV infection in drug treatment centers
The 
EXPLORE 
Randomized 
Controlled 
Study 114 
4295 HIV negative MSM age ≥ 16 
were randomized to 2 study arms to 
assess a behavioral intervention on 
HIV acquisition and  risk behavior: 
1. 10 core counselling sessions every
4-6 months followed by 7 booster 
sessions every 3 months 
2. 2 bi-annual brief counseling
sessions using RESPECT  model 
3. Participants received HIV test every
6 months 
HIV infection and risk behavior were 
measured every 6 months.  
HIV acquisition: 
- 15.7% lower rate in intervention group 
when adjusted for baseline covariates 
Significant findings for intervention: 
• Less reported any unprotected anal sex,
serodiscordant unprotected anal sex 
• Drug and alcohol use was associated with
unprotected anal sex 
• Suggests tailored behavioral intervention
was feasible to reduce HIV infection in 
MSM; need for interventions to address 
serodiscordant partner, drug and alcohol 
risk 
Men 
Maintaining 
Wellbeing and 
Healthy 
Relationships 
(HoMBReS)
115
30 soccer teams comprised of 222 
Latino men aged ≥18 were randomized 
to 2 study arms to assess a lay health 
advisor (LHA)  intervention on HIV 
testing and condom use: 
1. 15 soccer teams elected and trained
LHAs work with teammates 
2. 15 soccer teams served as the
control group with no LHA 
HIV infection and condom use were 
measured every 3 months.  
Significant findings for intervention: 
• More reported HIV testing at 18 months
• More reported consistent condom use with
all partners at 3 months
• Suggests LHA intervention was feasible to
increase HIV testing and condom use
among Latino men
Many Men, 
Many Voices 
(3MV)116 
338 HIV negative African American 
MSM ages ≥18 were randomized to 2 
study arms to assess a small group 
intervention on HIV testing and risk 
behavior: 
1. 6 consecutive 2-3 hour MSM
tailored HIV/STI prevention 
sessions at a weekend retreat 
2. Waitlist control group
HIV, STI, and risk behavior measured at 3, 6 
months. 
Significant findings for intervention: 
• Less reported any unprotected anal sex
with casual partners 
• Greater reported HIV testing
• Suggests tailored prevention intervention
was feasible to increase HIV testing and
reduce sex risk behavior among MSM
Table 3 Continued
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Strength 
Through 
Youth Livin’ 
Empowered 
(STYLE)117 
81 young MSM of color (mean 
age=21) were enrolled into a social 
marketing campaign intervention to 
assess HIV acquisition: 
1. Social marketing campaign,
targeted outreach and HIV testing, 
and a strongly linked medical and 
social support network  
HIV diagnosis for intervention group: 
• 2/3 newly diagnosed
• 1/3 diagnosed during the acute stage
• Suggests a social network campaign is a
feasible intervention to increase HIV
diagnosis among young MSM of color
Partner 
Counseling 
and Referral 
Services 
(PCRS)118 
Systematic review of 9 studies to 
assess partner notification, HIV testing 
and acquisition: 
• Provider referral-HIV positive
patient voluntarily discloses partner 
information and provider notifies  
• Patient referral-HIV positive patient
notifies partners 
• Contact referral-HIV positive
patient voluntarily discloses partner 
information and agrees to notify 
partners; provider notifies partners 
if not completed within time period 
Partner notification results: 
• 67% partners located and notified
• 63% partners were HIV tested
• 20% partners tested HIV positive
PCRS delivery results: 
• Little difference among 3 partner
notification delivery methods 
• Few studies assessed patient or contact
referral 
• Suggest provider referral PCRS effectively
increased HIV testing and diagnosis among 
Rapid HIV 
Testing in 
Community-
based 
Organizations 
(CBO)119 
23,900 rapid HIV antibody tests were 
administered to high risk individuals: 
• Trained CBO staff offered
counseling and rapid HIV testing to 
clients either in mobile testing units 
or inside venues that included parks, 
shelters, hotels, clubs, health fairs, 
syringe-exchange sites, and 
community clinics. 
HIV testing status 
• 30% never been tested
• 43% not tested in past year
Rapid HIV antibody test results: 
• 331 (1%) preliminary positive
• 286 (86%) received confirmatory test
• 267 (93%) confirmed HIV positive
• 17 (6%) confirmed HIV negative
• 94% positive predictive value
• Suggests rapid HIV testing conducted by
CBOs effectively identified HIV infection
among high risk populations
Rapid HIV 
Test 
Distribution 
(RTDP)120 
372,960 rapid HIV antibody tests were 
administered at 230 organizations by 
107 coordinators: 
• 121 state and local health
departments 
• 101 medical centers and
community-based organizations 
• 8 correctional facilities
• 48 coordinators were interviewed
Rapid HIV antibody test results: 
• 5,385 (1.4%) preliminary positive
• 4,650 (1.2%) confirmed HIV positive
• 79.1% confirmed results were provided to
clients
90% coordinators interviewed reported 
increased HIV screening was due to:  
• RTDP providing additional tests (81%)
• Clients did not have to return for a second
visit to receive results (79%)
• Suggests rapid HIV testing increased client
acceptance and staff availability to conduct
more testing
Table 3 Continued
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Emergency departments offer a healthcare setting to implement non-targeted routine HIV 
testing and identify high risk individuals, yet the fast pace, urgent nature of this setting has 
hindered utilization. A survey of emergency department providers showed they rarely encourage 
patients seeking STD treatment to receive an HIV test during their visit. Slightly more providers 
(35%) referred patients to seek HIV testing at outside sources; however, lack of follow-up 
services and poor compliance of patients render referrals less effective.104,121 Alternately, an 
analysis found emergency department testing identified more HIV infection than STD clinics and 
publicly funded sites.122 Providing HIV counseling in fast pace healthcare settings is less clear. 
HIV prevention counseling has been shown effective to reduce risk behavior in HIV positive 
individuals; but some studies have shown little effect of counseling on HIV negative 
individuals.109,123 Two randomized controlled trials assessing prevention counseling found the 
nature and duration of prevention counseling might influence its effectiveness.111,114 Routine 
testing in emergency departments may also help lift stigma and fear by normalizing HIV 
testing.124,125,126,127 
 
3.1 INDIVIDUAL EFFECTS: BENEFITS AND HARMS 
  
Knowledge of HIV status by receiving testing is important for both HIV positive and 
HIV negative individuals. Prompt entry into care and time to treatment is critical for HIV 
positive individuals to promote better health outcomes, and getting HIV tested is the first step to 
identify and guide these individuals to the appropriate resources. HIV positive persons who are 
unaware of their diagnosis are a missed opportunity to intervene in HIV progression to AIDS, 
which results in increased susceptibility to opportunistic infections and cancers that cause severe 
 32 
disease and death. The sooner an HIV positive person receives treatment with HAART increases 
their likelihood for survival. HIV testing has the potential to diagnose individuals at an early 
stage before symptoms develop with routing testing programs. Studies have shown many HIV 
positive individuals seen in healthcare settings while they are unaware of infection were not 
tested or diagnosed.103,108 Survival benefits for screening HIV positive patients and linking them 
to care has been shown to outweigh the substantial costs associated with HIV care.44,105,128  
Counseling and support groups help individuals cope with their HIV diagnosis. 
Becoming newly diagnosed with HIV can elicit many emotions such as fear, anger, sadness and 
concerns of death and stigma. Community organizations and peer groups for HIV support are 
excellent resources to alleviate individuals’ fear and enlighten them on the positive steps they 
can take to embrace their diagnosis and lead a healthy fulfilling life. Prevention counseling arms 
individuals with the knowledge and resources to go back into the community and practice safe 
goal behaviors. Knowing HIV status is a tool that can promote healthy behaviors to reduce HIV 
acquisition among HIV negative individuals, though studies on prevention counseling among 
persons who are HIV negative have mixed results on the adoption of risk reduction 
behaviors.103,104,111,114,123 Regardless of HIV status, individuals who seek testing and counseling 
may take the HIV health education knowledge gained back to their partner, friends, family, or 
community thus spreading positive promotion to get tested and practice harm reduction. 
 
3.2 OVERALL EFFECT ON PUBLIC HEALTH 
 
The benefit of early HIV diagnosis by testing is important for public health prevention 
efforts to reduce transmission to sex and needle sharing partners.129 Knowledge of HIV status 
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has been shown to greatly promote risk reduction among HIV positive individuals, which aids in 
the prevention of transmission because persons who are aware of their HIV-positive status take 
precautions to avoid infecting others.2 Data have shown HIV positive individuals significantly 
reduce their risk of transmitting HIV infection to others.2,51,52,53,54,55,56,57 Identifying HIV infected 
individuals at the earliest stage possible serves as an opportunity to intervene and control the in 
the spread of HIV infection even further. Expanding HIV testing can also help reduce stigma that 
still exists and prohibits individuals from seeking HIV testing.124,125,126 Increasing providers and 
healthcare professionals who practice routine HIV testing can increase acceptability among 
patients and normalize HIV testing.104 
The public health impact of universally screening the donated blood supply for HIV and 
screening and treating HIV positive pregnant women has been successful in significantly 
reducing blood donor recipient and perinatal transmission.130 Among pregnant women, screening 
has proven substantially more effective than risk-based testing for detecting unsuspected 
maternal HIV infection and preventing perinatal transmission.131,132,133 Public health 
interventions to reduce risk behaviors such as needle exchange programs have also had success 
among IDU; however reducing high risk sexual behavior, such as condom use, has not proven as 
effective.134,135,136,137,138 The public health impact of HAART treatment as prevention of HIV 
transmission rests on the identification of HIV infected at risk for transmitting and partners of 
HIV positive individuals at risk for acquisition. 
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4.0  FOURTH CHAPTER: FUTURE DIRECTIONS OF HIV TESTING 
 
Programs to increase HIV testing should identify high risk individuals, promote entry and 
retention into care, and retain follow up for continuing treatment. Comprehensive HIV programs, 
such as the Pittsburgh AIDS Task Force, include testing, prevention and education counseling, 
case management, and referral serves for diagnosis and treatment of HIV, treatment of co-
infections, follow-up and retention in care. Despite the effectiveness of such programs, many 
HIV positive individual remain unaware they are infected. These individuals may benefit from 
non-targeted routine testing programs in healthcare settings such as emergency departments and 
urgent care providers. Studies have shown testing in emergency departments increase the number 
of early diagnosed HIV infection.139,140 Hospital emergency departments and urgent care centers 
offer an alternative setting to test a large number of individuals for HIV infection who normally 
would not seek testing.141,142,143 However, time restraints, lack of funding, and limited staff  have 
hindered uptake of HIV testing in emergency departments.140 Another major concern is linkage 
and subsequent follow up to ensure the patient enters into HIV care. Strategies need to be in 
place to collect or update correct contact information, establish provider-patient trust, and 
allocate staff effort to formulate linkage to care relationships with the patient and HIV specific 
provider.143 A cost-analysis found non-targeted HIV testing in an emergency department was 
less cost-effective, but identifies more HIV infection previously undiagnosed.139 Improvements 
to reduce costs associated with HIV testing in emergency departments are needed.  
National recommendations have called for increased efforts to diagnose early HIV 
infection. The CDC recently released an algorithm shown to accurately detect HIV before 
antibodies have developed using 4th generation antibody tests that measure the HIV p24-antigen 
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directly and confirming with HIV-1/HIV-2 differentiation tests.144,145 Studies demonstrated this 
algorithm performed better than the western blot at identifying acute phase HIV-1 infection and 
differentiating between HIV-1 and HIV-2 infection.146,147 The CDC reported results from two 
HIV screening programs evaluating this diagnostic algorithm.145 Among patients aged 18-64 
seen at an emergency department in Phoenix, Arizona, the CDC testing algorithm identified 37 
undiagnosed HIV infections and 12 (34%) acute phase HIV infections. The Screening Targeted 
Populations to Interrupt On-going Chains of HIV Transmission with Enhanced Partner 
Notification (STOP) study program identified 654 (1.7%) of 37,876 patients aged 12 or older 
reactive for the 4th generation immune assay and further differentiated for HIV-1 (n=554; 84.7%) 
and for both HIV-1 and HIV-2 (n=1; 0.2%). Of the remaining 99 patients with a negative or 
indeterminate differentiation test result, confirmatory testing found HIV-1 RNA present in 55 
patients who were 4th generation immune assay positive. Both screening programs conducted 4th 
generation HIV testing with the Architect HIV Ag/Ab Combo Assay (Abbott Diagnostics) and 
HIV-1/HIV-2 antibody differentiation with the Multispot HIV-1/HIV-2 Rapid Test (Bio-Rad 
Laboratories). Analysis from these studies found this HIV testing algorithm reduced missed 
diagnoses in 32% of the HIV positive patients at the Phoenix, Arizona emergency department 
program and 9% of patients in the STOP programs.  These finding suggest non-targeted HIV 
testing with a 4th generation immune assay in emergency departments and acute care settings can 
improve diagnosis of acute HIV infection. 
Home HIV rapid tests are now available for purchase and can be conducted in the privacy 
of ones’ own home with the hopes of attracting individuals at risk for HIV who would not 
normally seek testing.148,149 Studies have shown untrained participants were able to easily 
perform the test, accurately interpret the results, and understood the need for confirmatory 
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testing.150,151,152 One study reporting the use of home tests in HIV discordant MSM couples 
found regular testing with at home HIV rapid tests reduced risky behavior practices.153 The 
marketing of home HIV tests aims to breakthrough certain barriers that prevented uptake of 
testing at clinics such as confidentiality and stigma fears; however issues surround the 
affordability of the test. The likelihood that high risk individuals will be able to afford the cost of 
the test is low and there is concern of disproportionate testing among healthy individuals at low 
risk for HIV infection.154 There are some concerns about an individuals’ reaction to a positive 
result in the absence of a trained counselor; however experts believe the wealth of resources 
available for HIV rapid test positive individuals are sufficient.155 Lack of an HIV professional 
also limits the opportunity to accurately explain the window period. Data and trends for uptake 
of home tests are not yet available, and mixed view of optimism and skepticism surround the 
potential impact on diagnosing more individuals to help combat the HIV epidemic in the U.S.   
Public health interventions to reduce the spread of HIV have been effective, but not 
sufficient. New approaches to prevention are needed to halt the HIV epidemic. Increasing the 
acceptability and utilization of HIV testing by both healthcare professionals and individuals 
requires a comprehensive and coordinated approach. In addition to maintaining non-healthcare 
programs that target vulnerable and underserved population, routine non-targeted HIV testing in 
healthcare settings, mainly emergency departments, and home testing offer promise to identify 
new HIV diagnosis.  
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